Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light therapy glasses aim to zap daytime fatigue in sleep apnea patients

NCT ID NCT05917119

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether wearing bright light therapy glasses can reduce daytime sleepiness and depressive symptoms in people with obstructive sleep apnea who still feel tired despite using their CPAP machine. Sixty participants will wear the glasses for four weeks of active treatment and four weeks of sham (inactive) treatment, in random order. The goal is to see if the light improves alertness and mood beyond what CPAP alone provides.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented diagnosis of OSA * Currently on CPAP or BiPAP for at least 3 months * with documented adherence (defined as wearing CPAP/BiPAP for \>6h/night on at least 75% of nights), and adequate control of sleep apnea, as indicated by an AHI of 10 or less when on CPAP * Excessive residual daytime sleepiness (Epworth score \> 10) * If taking alertness promoting medication, the investigators will require that they are on a stable dose for at least one month prior to entering the study and that they refrain from dose changes while participating in the study * If already prescribed BLT, subjects must not have used it for at least one month prior to participating Exclusion Criteria: * Shift work * Travel across time zones in the past month * Narcolepsy * Regular hypnotics use * Decompensated congestive heart failure (CHF) * Primary central sleep apnea, needing O2 therapy via nasal cannula * Poorly controlled diabetes (HgA1c\>8%) * Active substance use disorder * Dementia * Untreated bipolar disorder * the investigators will consider individuals with a diagnosis of bipolar disorder who are currently in treatment and stable * Macular degeneration, recent lasik surgery (within 3 months) * Legally blind * Taking medication that will cause photosensitivity to blue-green light spectrum wavelength * Already using bright light therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    RECRUITING

    Pittsburgh, Pennsylvania, 15240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.